We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Urges Sponsors to Loosen Exclusion Criteria to Improve Trial Diversity
FDA Urges Sponsors to Loosen Exclusion Criteria to Improve Trial Diversity
Drug sponsors should think about loosening up their exclusion criteria—especially when recruiting for later stage trials, the FDA says in new draft guidance document published Thursday.